<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80167">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061748</url>
  </required_header>
  <id_info>
    <org_study_id>1160.192</org_study_id>
    <nct_id>NCT02061748</nct_id>
  </id_info>
  <brief_title>The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage</brief_title>
  <official_title>The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Humana Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct
      comparative safety and effectiveness studies of dabigatran and warfarin using real world
      data from Humana's health plan operations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>up to 21 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding</measure>
    <time_frame>up to 21 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major intracranial bleeding</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major extracranial bleeding</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major GI bleeding</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major upper GI bleeding</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major lower GI bleeding</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major urogenital bleeding</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major other bleeding</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attack</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Thromboembolism</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep Vein Thrombosis</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>up to 21 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Retrospective Chart Review</description>
    <arm_group_label>dabigatran</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        NVAF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient must have at least one inpatient, one physician office visit, or one
             emergency room visit with a diagnosis of AF on the index date or during the pre-index
             period.

          -  Patients must be continuously enrolled in a health plan during the pre-index period

          -  Patient must have a prescription for dabigatran or warfarin

          -  Patient must be treatment naive from all oral anticoagulant (OAC) use prior to first
             OAC prescription

          -  Aged 18-89 years on the index date. The index date is defined as the date of the
             first OAC prescription

        Exclusion criteria:

          -  Diagnosis of hyperthyroidism during the pre-index period,

          -  Having claims for any of the following within 3 months prior to the first diagnosis
             of AF: cardiac surgery, pericarditis, myocarditis, pulmonary embolism.

          -  Any patients with at least one medical claim for valvular heart disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
